

Comparative integromics on Angiopoietin family members

YURIKO KATOH¹ and MASARU KATOH²

¹M&M Medical BioInformatics, Hongo 113-0033; ²Genetics and Cell Biology Section,
National Cancer Center Research Institute, Tokyo 104-0045, Japan

Received February 6, 2006; Accepted March 2, 2006

Abstract. Angiopoietin-1 (ANGPT1), Angiopoietin-4 (ANGPT4), VEGF, FGF2, FGF4, HGF, Ephrin, IL8 and CXCL12 (SFD1) are pro-angiogenic factors (angiogenic activators), while Angiopoietin-2 (ANGPT2), Angiostatin, Endostatin, Tumstatin, Canstatin, THBS1, THBS2, TNFSF15 (VEGI) and Vasohibin (VASH1) are anti-angiogenic factors (angiogenic inhibitors). ANGPT1 and ANGPT2 are ligands for TIE family receptor tyrosine kinases, TIE1 and TIE2 (TEK). Angiopoietin family consists of ANGPT1, ANGPT2, ANGPT4, ANGPTL1 (ANGPT3), ANGPTL2, ANGPTL3 (ANGPT5), ANGPTL4, ANGPTL5, ANGPTL6 and ANGPTL7. TCF/LEF binding sites within the promoter region of human Angiopoietin family members were searched for by using bioinformatics and human intelligence (Humint). Because four TCF/LEF-binding sites were identified within the human *ANGPTL7* promoter, comparative genomics analyses on *ANGPTL7* orthologs were further performed. *ANGPTL7* gene at human chromosome 1p36.22 was located within intron 28 of *FRAP1* gene encoding mTOR protein. Chimpanzee *ANGPTL7* gene, consisting of five exons, was located within NW_101546.1 genome sequence. Chimpanzee *ANGPTL7* showed 99.4% and 86.1% total-amino-acid identity with human *ANGPTL7* and mouse *Angptl7*, respectively. Human *ANGPTL7* mRNA was expressed in neural tissues, keratoconus cornea, trabecular meshwork, melanotic melanoma and uterus endometrial cancer, while mouse *Angptl7* mRNA was expressed in four-cell embryo, synovial fibroblasts, thymus, uterus and testis. Four TCF/LEF-binding sites within human *ANGPTL7* promoter were conserved in chimpanzee *ANGPTL7* promoter; however, only an unrelated TCF/LEF-binding site occurred in mouse and rat *Angptl7* promoters. Human *ANGPTL7*, characterized as potent target gene of WNT/ β -catenin signaling pathway, is a pharmacogenomics target in the fields of oncology and regenerative medicine.

Correspondence to: Dr Masaru Katoh, Genetics and Cell Biology Section, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
E-mail: mkatoh@ncc.go.jp

Key words: bioinformatics, comparative genomics, comparative proteomics, Angiopoietin, WNT, integrome network, systems medicine

Introduction

Angiogenesis is regulated by the balance between pro-angiogenic factors (angiogenic activators) and anti-angiogenic factors (angiogenic inhibitors) (1-6). Angiopoietin-1 (ANGPT1), Angiopoietin-4 (ANGPT4), VEGF, FGF2, FGF4, HGF, Ephrin, IL8 and CXCL12 (SFD1) are pro-angiogenic factors, while Angiopoietin-2 (ANGPT2), Angiostatin, Endostatin, Tumstatin, Canstatin, THBS1, THBS2, TNFSF15 (VEGI) and Vasohibin (VASH1) are anti-angiogenic factors (1-17).

ANGPT1, ANGPT2, ANGPT4 are ligands for TIE family receptor tyrosine kinases, TIE1 and TIE2 (TEK) (7-9). ANGPTL1 (ANGPT3), ANGPTL2, ANGPTL3 (ANGPT5), ANGPTL4, ANGPTL5, ANGPTL6 and ANGPTL7 (18-23) are related to ANGPT1, ANGPT2 and ANGPT4. Angiopoietin family consists of ANGPT1, ANGPT2, ANGPT4, ANGPTL1, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL5, ANGPTL6 and ANGPTL7.

WNT, FGF, Notch and Hedgehog signaling pathways network together during embryogenesis, tissue regeneration and carcinogenesis (24-33). Canonical WNT signals are transduced to the transcriptional complex consisting of TCF/LEF, β -catenin, BCL9/BCL9L and PYGO1/PYGO2 to activate transcription of target genes, such as *DKK1*, *DKK4*, *FGF18* and *FGF20* (34-43); however, WNT-dependent transcriptional regulation of Angiopoietin family members remains unclear.

Here, TCF/LEF binding sites within the promoter region of human Angiopoietin family members were searched for by using bioinformatics and human intelligence (Humint). Because four TCF/LEF-binding sites were identified in the 5'-promoter region of human *ANGPTL7* gene, comparative genomics analyses on *ANGPTL7* orthologs were further performed.

Materials and methods

WNT target gene screening. Genome sequences corresponding to human *ANGPT1*, *ANGPT2*, *ANGPT4*, *ANGPTL1*, *ANGPTL2*, *ANGPTL3*, *ANGPTL4*, *ANGPTL5*, *ANGPTL6* and *ANGPTL7* genes were searched for with BLAST programs (<http://www.ncbi.nlm.nih.gov>) as described previously (44-47). TCF/LEF-binding sites within the 5'-flanking promoter region of the above genes were searched for based on bioinformatics and manual inspection as described previously (38-42,48).

Identification of chimpanzee and cow *ANGPTL7* orthologs. Chimpanzee and cow genome sequences homologous to




Figure 1. (A), Human Angiopoietin gene family. Gene symbol, complete coding sequence, genome sequence and the number of TCF/LEF-binding sites within promoter region of Angiopoietin family genes are listed. Four TCF/LEF-binding sites exist within the human *ANGPTL7* promoter. (B), Phylogenetic analysis on human and mouse Angiopoietin family members. Hs, human; Mm, mouse. (C), *ANGPTL7* locus at human chromosome 1p36.22. *ANGPTL7* gene, consisting of five exons, is located within intron 28 of the *FRAP1* gene.

human *ANGPTL7* were searched for with BLAST programs as described previously (49-52). TCF/LEF-binding sites within the 5'-flanking promoter region of *ANGPTL7* orthologs were also searched for.

Comparative proteomics analysis. Phylogenetic analysis on ANGPT family proteins was performed by using the CLUSTALW program.

Comparative genomics analyses. Phylogenetic analysis on promoter of *ANGPTL7* orthologs was performed by using the CLUSTALW program. Promoter region of human and chimpanzee *ANGPTL7* orthologs were aligned by using the Genetyx program and manual curation as described previously (53-56).

In silico expression analyses. Expressed sequence tags (ESTs) derived from human *ANGPTL7* gene and mouse *Angptl7* gene were searched for by using the BLAST programs. The sources of human *ANGPTL7* ESTs and those of mouse *Angptl7* ESTs were listed up for *in silico* expression analyses.

Results

Screening of the TCF/LEF-binding site within promoter region of Angiopoietin family genes. Human ANGPT1 RefSeq (NM_001146.3), ANGPT2 RefSeq (NM_001147.1), ANGPT4 RefSeq (NM_015985.2), ANGPTL1 RefSeq (NM_004673.3), ANGPTL2 RefSeq (NM_012098.2), ANGPTL3 RefSeq (NM_014495.2), ANGPTL4 RefSeq (NM_139314.1), ANGPTL5 RefSeq (NM_178127.2), ANGPTL6 RefSeq (NM_031917.2) and ANGPTL7 RefSeq (NM_021146.2) were used as query sequences for the BLAST programs to identify genome clones corresponding to Angiopoietin family genes. The 5'-flanking promoter region of human *ANGPT1*,

ANGPT2, *ANGPT4*, *ANGPTL1*, *ANGPTL2*, *ANGPTL3*, *ANGPTL4*, *ANGPTL5*, *ANGPTL6* and *ANGPTL7* genes were identified within AC053479.8, AC018398.10, AL050325.20, AL355520.8, AL356862.10, AL138847.14, AC010323.8, AP002372.4, AC020931.6 and AL391561.20 genome sequences, respectively (Fig. 1A). TCF/LEF-binding sites within the 5'-promoter region of human Angiopoietin family genes were then searched for based on manual inspection. Four TCF/LEF-binding sites were identified within human *ANGPTL7* promoter (Fig. 1A).

Identification of chimpanzee *ANGPTL7* ortholog. BLAST programs using human *ANGPTL7* RefSeq revealed that chimpanzee *ANGPTL7* gene was located within NW_101546.1 genome sequence (Fig. 2A). Exon-intron boundaries of the chimpanzee *ANGPTL7* gene were determined based on the consensus sequence of exon-intron junctions. Chimpanzee *ANGPTL7* gene was found consisting of five exons.

Compared with human *ANGPTL7* RefSeq, one-base insertion occurred at exon 3 of chimpanzee *ANGPTL7* gene within NW_101546.1 genome sequence. Re-sequencing of the genome sequence around exon 3 of chimpanzee *ANGPTL7* gene should be done in the future to correct the sequencing error.

Complete coding sequence (CDS) of chimpanzee *ANGPTL7* was determined in this study by assembling nucleotide sequences of five exons (Fig. 2A). Genetyx program revealed that nucleotide position 241-1281 was the coding region of chimpanzee *ANGPTL7* complete CDS. Chimpanzee *ANGPTL7* gene was found to encode a 346-amino-acid *ANGPTL7* protein (Fig. 2A).

Comparative proteomics analysis on *ANGPTL7* orthologs. Phylogenetic analysis on human and mouse Angiopoietin family members revealed that *ANGPTL7* orthologs were




Figure 2. Chimpanzee ANGPTL7. (A), Nucleotide and amino-acid sequences of chimpanzee ANGPTL7 complete CDS. Nucleotides and amino-acid residues are numbered on the right. (B), Alignment of ANGPTL7 orthologs. Hs, human; Pt, chimpanzee; Mm, mouse. Conserved amino-acid residues are shown by asterisks.




Figure 3. Alignment of the human and chimpanzee ANGPTL7 promoters. Hs, human; Pt, chimpanzee. Region corresponding to exon 1 of the human ANGPTL7 gene is boxed. TCF/LEF-binding sites are shown by double over-lines.

relatively well conserved (Fig. 1B). Chimpanzee ANGPTL7 showed 99.4% and 86.1% total-amino-acid identity with human ANGPTL7 and mouse Angptl7, respectively (Fig. 2B).

Intra-species comparative genomics analysis on ANGPTL7 orthologs. ANGPTL7 gene was located within FRAP1 gene at human chromosome 1p36.22 (Fig. 1C). Paralog of FRAP1 gene, encoding mTOR protein, was not identified within the human genome. ANGPTL7 gene was found consisting of 5 exons, while FRAP1 gene was found consisting of 58 exons.

ANGPTL7 gene was located within intron 28 of FRAP1 gene in the anti-sense direction (Fig. 1C). These facts indicate that ANGPTL7 gene was inserted into the FRAP1 gene during evolution.

Expression profile of human ANGPTL7 and mouse Angptl7 mRNAs. In silico expression analyses were performed to compare the expression profiles of human ANGPTL7 and mouse Angptl7 mRNAs. Human ANGPTL7 mRNA was expressed in neural tissues, keratoconjunctiva, trabecular

meshwork, melanotic melanoma and uterus endometrial cancer, while mouse *Angptl7* mRNA was expressed in four-cell embryo, synovial fibroblasts, thymus, uterus and testis.

Comparative genomics analyses on ANGPTL7 promoters. Human and chimpanzee *ANGPTL7* promoters were located within AL391561.20 and NW_101546.1 genome sequences, respectively, as mentioned above. BLAST programs revealed that cow, mouse and rat *Angptl7* promoters were located within AC174033.2, AC108508.2 and AC125863.3 genome sequences, respectively. Cow *Angptl7* promoter was not used for the following comparative genomics analyses, because one of sequencing gaps within the AC174033.2 genome sequence corresponded to the cow *Angptl7* promoter region.

GC contents of human, chimpanzee, mouse and rat *ANGPTL7* promoters were 41.5%, 41.4%, 50.2% and 50.6%, respectively. GC contents of primate *ANGPTL7* promoters were lower than those of rodent *Angptl7* promoters.

Four TCF/LEF-binding sites within human *VEGFD* promoter were located about 1050, 900, 600, and 550 bp upstream of the transcription start site (Fig. 3). Four TCF/LEF-binding sites within the human *ANGPTL7* promoter were conserved in chimpanzee *ANGPTL7* promoter; however, only an unrelated TCF/LEF-binding site occurred in the mouse and rat *Angptl7* promoters.

Discussion

TCF/LEF binding sites within the promoter region of human *ANGPT1*, *ANGPT2*, *ANGPT4*, *ANGPTL1*, *ANGPTL2*, *ANGPTL3*, *ANGPTL4*, *ANGPTL5*, *ANGPTL6* and *ANGPTL7* genes were searched for in this study. Because four TCF/LEF-binding sites were identified within the human *ANGPTL7* promoter (Fig. 1A), comparative genomics analyses on *ANGPTL7* orthologs were further performed.

ANGPTL7 gene at human chromosome 1p36.22 was located within intron 28 of the *FRAP1* gene encoding mTOR protein (Fig. 1C). Chimpanzee *ANGPTL7* gene, consisting of five exons, was located within the NW_101546.1 genome sequence (Fig. 2A). Chimpanzee *ANGPTL7* showed 99.4% and 86.1% total-amino-acid identity with human *ANGPTL7* and mouse *Angptl7*, respectively (Fig. 2B).

Four TCF/LEF-binding sites within the human *ANGPTL7* promoter were conserved in chimpanzee *ANGPTL7* promoter (Fig. 3); however, only an unrelated TCF/LEF-binding site occurred in the mouse and rat *Angptl7* promoters. GC contents of primate *ANGPTL7* promoters were lower than those of rodent *Angptl7* promoters. Human *ANGPTL7* mRNA was expressed in neural tissues, keratoconus cornea, trabecular meshwork, melanotic melanoma and uterus endometrial cancer, while mouse *Angptl7* mRNA was expressed in four-cell embryo, synovial fibroblasts, thymus, uterus and testis. Together these facts indicate that expression profiles of primate *ANGPTL7* orthologs and rodent *Angptl7* orthologs differ due to promoter evolution.

Human *ANGPTL7*, characterized as a potent target gene of WNT/ β -catenin signaling pathway, is a pharmacogenomics target in the fields of oncology and regenerative medicine.

References

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1: 27-31, 1995.
2. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 86: 353-364, 1996.
3. Kerbel RS and Folkman J: Clinical translation of angiogenesis inhibitors. *Nat Rev Cancer* 2: 727-739, 2002.
4. Carmeliet P: Angiogenesis in life, disease and medicine. *Nature* 438: 932-936, 2005.
5. Coultas L, Chawengsaksophak K and Rossant J: Endothelial cells and VEGF in vascular development. *Nature* 438: 937-945, 2005.
6. Kerbel RS: Vasohibin: the feedback on a new inhibitor of angiogenesis. *J Clin Invest* 114: 884-886, 2004.
7. Suri C, Jones PF, Patan S, *et al*: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* 87: 1171-1180, 1996.
8. Maisonpierre PC, Suri C, Jones PF, *et al*: Angiopoietin-2, a natural antagonist for Tie2 that disrupts *in vivo* angiogenesis. *Science* 277: 55-60, 1997.
9. Valenzuela DM, Griffiths JA, Rojas J, *et al*: Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. *Proc Natl Acad Sci USA* 96: 1904-1909, 1999.
10. Tammela T, Enholm B, Alitalo K and Paavonen K: The biology of vascular endothelial growth factors. *Cardiovasc Res* 65: 550-563, 2005.
11. Schweigerer L, Neufeld G, Friedman J, *et al*: Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. *Nature* 325: 257-259, 1987.
12. Zugmaier G, Lippman ME and Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. *J Natl Cancer Inst* 84: 1716-1724, 1992.
13. Rasmussen HS, Rasmussen CS, Macko J and Yonehiro G: Angiogenic gene therapy strategies for the treatment of cardiovascular disease. *Curr Opin Mol Ther* 4: 476-481, 2002.
14. Langer R, Conn H, Vacanti J, Haudenschild C and Folkman J: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. *Proc Natl Acad Sci USA* 77: 4331-4335, 1980.
15. Kalluri R: Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. *Cold Spring Harb Symp Quant Biol* 67: 255-266, 2002.
16. Bocci G, Francia G, Man S, Lawler J and Kerbel RS: Thrombospondin-1, a mediator of the anti-angiogenic effects of low-dose metronomic chemotherapy. *Proc Natl Acad Sci USA* 100: 12917-12922, 2003.
17. Watanabe K, Hasegawa Y, Yamashita H, *et al*: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. *J Clin Invest* 114: 898-907, 2004.
18. Kim I, Moon SO, Koh KN, *et al*: Molecular cloning, expression, and characterization of angiopoietin-related protein. Angiopoietin-related protein induces endothelial cell sprouting. *J Biol Chem* 274: 26523-26528, 1999.
19. Conklin D, Gilbertson D, Taft DW, *et al*: Identification of a mammalian angiopoietin-related protein expressed specifically in liver. *Genomics* 62: 477-482, 1999.
20. Yoon JC, Chickering TW, Rosen ED, *et al*: Peroxisome proliferator-activated receptor γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. *Mol Cell Biol* 20: 5343-5349, 2000.
21. Zeng L, Dai J, Ying K, *et al*: Identification of a novel human angiopoietin-like gene expressed mainly in heart. *J Hum Genet* 48: 159-162, 2003.
22. Oike Y, Yasunaga K, Ito Y, *et al*: Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. *Proc Natl Acad Sci USA* 100: 9494-9499, 2003.
23. Peek R, Kammerer RA, Frank S, Otte-Holler I and Westphal JR: The angiopoietin-like factor cornea-derived transcript 6 is a putative morphogen for human cornea. *J Biol Chem* 277: 686-693, 2002.
24. Katoh M: *WNT* and *FGF* gene clusters. *Int J Oncol* 21: 1269-1273, 2002.
25. Katoh M: Epithelial-mesenchymal transition in gastric cancer. *Int J Oncol* 27: 1677-1683, 2005.
26. Katoh Y and Katoh M: FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. *Int J Mol Med* 17: 529-532, 2006.

27. Li JL and Harris AL: Notch signaling from tumor cells: a new mechanism of angiogenesis. *Cancer Cell* 8: 1-3, 2005.
28. Katoh M and Katoh M: Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. *Int J Mol Med* 17: 681-685, 2006.
29. Lawson ND, Vogel AM and Weinstein BM: Sonic hedgehog and vascular endothelium growth factor act upstream of Notch pathway during arterial endothelial differentiation. *Dev Cell* 3: 127-136, 2002.
30. Katoh Y and Katoh M: Comparative genomics on HHIP family orthologs. *Int J Mol Med* 17: 391-395, 2006.
31. Katoh Y and Katoh M: Hedgehog signaling in gastric cancer. *Cancer Biol Ther* 4: 1050-1054, 2005.
32. Garciadiego-Cazares D, Rosales C, Katoh M and Chimal-Monroy J: Coordination of chondrocyte differentiation and joint formation by $\alpha 5\beta 1$ integrin in the developing appendicular skeleton. *Development* 131: 4735-4742, 2004.
33. Katoh Y and Katoh M: WNT antagonist, SFRP1, is Hedgehog signaling target. *Int J Mol Med* 17: 171-175, 2006.
34. Katoh M: Regulation of WNT signaling molecules by retinoic acid during neuronal differentiation in NT2 cells: threshold model of WNT action. *Int J Mol Med* 10: 683-687, 2002.
35. Katoh M and Katoh M: Identification and characterization of human *BCL9L* gene and mouse *Bcl9l* gene *in silico*. *Int J Mol Med* 12: 643-649, 2003.
36. Heller RS, Klein T, Ling Z, Heimberg H, Katoh M, Madsen OD and Serup P: Expression of *WNT*, *Frizzled*, *sFRP*, and *DKK* genes in adult human pancreas. *Gene Expr* 11: 141-147, 2003.
37. Swain RK, Katoh M, Medina A and Steinbeisser H: *Xenopus* frizzled-4S, a splicing variant of *Xfz4*, is a context-dependent activator and inhibitor of Wnt/ β -catenin signaling. *Cell Commun Signal* 3: 12, 2005.
38. Katoh Y and Katoh M: Comparative genomics on *DKK1* orthologs. *Int J Oncol* 27: 275-279, 2005.
39. Katoh Y and Katoh M: Comparative genomics on *DKK2* and *DKK4* orthologs. *Int J Mol Med* 16: 477-481, 2005.
40. Katoh Y and Katoh M: Comparative genomics on *FGF16* orthologs. *Int J Mol Med* 16: 959-963, 2005.
41. Katoh M and Katoh M: Comparative genomics on *FGF8*, *FGF17*, and *FGF18* orthologs. *Int J Mol Med* 16: 493-496, 2005.
42. Katoh M and Katoh M: Comparative genomics on *FGF20* orthologs. *Oncol Rep* 14: 287-290, 2005.
43. Katoh M: WNT2B: comparative integromics and clinical application. *Int J Mol Med* 16: 1103-1108, 2005.
44. Katoh M: Paradigm shift in gene-finding method: from bench-top approach to desk-top approach. *Int J Mol Med* 10: 677-682, 2002.
45. Katoh M and Katoh M: Identification and characterization of human *HES2*, *HES3*, and *HES5* genes *in silico*. *Int J Oncol* 25: 529-534, 2004.
46. Katoh M and Katoh M: Identification and characterization of human *HESL*, rat *Hesl* and rainbow trout *hesl* genes *in silico*. *Int J Mol Med* 14: 747-751, 2005.
47. Katoh Y and Katoh M: Identification and characterization of rat *Wnt6* and *Wnt10a* genes *in silico*. *Int J Mol Med* 15: 527-531, 2005.
48. Katoh Y and Katoh M: Comparative genomics on *SLIT1*, *SLIT2*, and *SLIT3* orthologs. *Oncol Rep* 14: 1351-1355, 2005.
49. Katoh Y and Katoh M: Identification and characterization of rat *Wnt1* and *Wnt10b* genes *in silico*. *Int J Oncol* 26: 841-845, 2005.
50. Katoh M and Katoh M: Comparative genomics on *WNT8A* and *WNT8B* genes. *Int J Oncol* 26: 1129-1133, 2005.
51. Katoh M: Molecular evolution of *WNT2B* orthologs. *Int J Oncol* 26: 1135-1139, 2005.
52. Katoh M: Comparative genomics on *WNT3-WNT9B* gene cluster. *Int J Mol Med* 15: 743-747, 2005.
53. Katoh M and Katoh M: Comparative genomics on *WNT5A* and *WNT5B* genes. *Int J Mol Med* 15: 749-753, 2005.
54. Katoh Y and Katoh M: Comparative genomics on *WNT11* gene. *Int J Mol Med* 15: 879-883, 2005.
55. Katoh Y and Katoh M: Comparative genomics on *VANGL1* and *VANGL2* genes. *Int J Oncol* 26: 1435-1440, 2005.
56. Katoh Y and Katoh M: Comparative genomics on *SFRP1* orthologs. *Int J Oncol* 27: 861-865, 2005.